Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3997 | Skin biopsy Wiki | 1.00 |
drug663 | Blood sampling Wiki | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
D006333 | Heart Failure NIH | 0.25 |
D003866 | Depressive Disorder NIH | 0.17 |
D001008 | Anxiety Disorders NIH | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001635 | Congestive heart failure HPO | 0.25 |
HP:0000716 | Depressivity HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
Heart failure (HF) is a complex clinical syndrome characterized by inability of the heart to pump an adequate amount of blood. Heart failure affects patients' ability to carry out even simple activities of daily living and therefore has negative psychological impact. Many studies reported that depression is prevalent among HF patients and it is being associated with high morbidity, mortality and costs. The European Society of Cardiology guidelines stresses the importance of routine depression screening with a validated questionnaire and initiating treatment for depression for all depressed HF patients and their access to psychological treatment. The community heart failure nurses provide the integrated heart failure service in the local area of Southwark and Lambeth in South London. The aim of the integrated heart failure team in the community is to provide the HF treatment effectively, help patients understand and manage their symptoms and support with lifestyle changes. Even though, the community HF nurses have extensive role in managing HF patients in the community, their role in assessing anxiety and depression; and providing psychological treatment needs to be further explored. Therefore, there is a need to assess the process by which community HF nurses assess and manage anxiety and depression. This current study builds on our recent systematic review which illustrated how cognitive behaviour therapy is effective at improving depressive symptoms in HF, but more studies are needed to build on these findings. The findings from this review will be used to examine the perspectives on assessing, managing and treating depression and anxiety in HF patients. In this current study, an online focus group with community heart failure nurses and qualitative telephone/online interviews with community-based HF patients will be undertaken to explore their views and experiences in managing depression and anxiety; and to assess whether COMPASS a web-based intervention would be useful. Also, this study will explore the impact of COVID-19 on the psychological wellbeing of community-based HF patients.
Description: will explore nurses' perception regarding the assessment and management of depression and anxiety in heart failure by undertaking an online focus group with community heart failure nurses.
Measure: Explore community heart failure nurses' perception of assessing, managing and treating depression and anxiety in HF and the use of web-based interventions. Time: This will take place before the introduction of COMPASS web-based intervention.Description: will explore patients' perception regarding the assessment and management of depression and anxiety in heart failure. This will be done by undertaking online\telephone interviews with community-based heart failure patients.
Measure: Explore community heart failure patients' perception of assessing, managing and treating depression and anxiety in HF and the use of web-based interventions. Time: This will take place before the introduction of COMPASS web-based intervention.Description: will explore nurses' perception regarding the use of web-based COMPASS intervention for the management of depression and anxiety in heart failure in an online focus group.
Measure: Explore nurses' perception of using web-based COMPASS intervention for depression and anxiety management in HF Time: This will take place 30 minutes after the introduction and demonstration of COMPASS web-based intervention.Description: will explore patients' perception regarding the use of web-based COMPASS intervention for the management of depression and anxiety in heart failure. This will be done by conducting online\telephone interviews with community-based heart failure patients.
Measure: Explore patients' perception of using web-based COMPASS intervention for depression and anxiety management in HF Time: This will take place 30 minutes after the introduction and demonstration of COMPASS web-based intervention.Description: will discuss with community HF nurses the impact of COVID-19 on the psychological wellbeing of community-based HF patients and how it changed their access to psychological intervention. This will form part of the online focus group.
Measure: Explore with community HF nurses the impact of COVID-19 pandemic on HF patients' depression and anxiety level and changes to management processes. Time: This will take place before the introduction of COMPASS web-based intervention.Description: will explore with community HF patients the impact of COVID-19 on the psychological wellbeing of community-based HF patients and how it changed their access to psychological intervention. This will form part of the online/telephone interviews.
Measure: Explore with community HF patients the impact of COVID-19 pandemic on HF patients' depression and anxiety level and changes to management processes. Time: This will take place before the introduction of COMPASS web-based intervention.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports